Incyte

News

Reuters - 20 minutes ago

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change Bath & Body Works Inc BBWI.N +6.5% Intel Corp INTC.OQ +6.4% Oracle Corp ORCL.N +4.9% Incyte Corp INCY.OQ +4.3% Vistra Corp VST.N +4.2% Bottom Performers Percent Change Qorvo Inc QRVO.OQ -6.9% Skyworks Solutions Inc SWKS.OQ -5.9% Micron

Reuters - 13 hours ago

U.S. Avalonbay Communities, Elf Beauty, Evercore

U.S. RESEARCH ROUNDUP-Avalonbay Communities, Elf Beauty, Evercore Sept 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Avalonbay Communities, Elf Beauty and Evercore on Monday. HIGHLIGHTS * Avalonbay Communities Inc AVB.N : JP Morgan raises target price to $247 from $212 * Colgate-Palmolive Co CL.N : Wells Fargo cuts to underweight from equal-weight * Elf Beauty Inc ELF.N : Piper Sandler cuts target price to $162

Reuters - 1 month ago

Incyte's blood cancer drug succeeds late-stage trial

Incyte's blood cancer drug succeeds late-stage trial Aug 15 (Reuters) - Incyte INCY.O said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer. The company said its drug Monjuvi, combined with Bristol Myers Squibb's BMY.N drug, Revlimid, and Biogen's BIIB.O Rituxan achieved progression free survival in patients with follicular lymphoma (FL), when compared to Rituxan and Revlimid alone.

Reuters - 1 month ago

Incyte Announces Topline Results From Study Of Tafasitamab (Monjuvi®)

BRIEF-Incyte Announces Topline Results From Study Of Tafasitamab (Monjuvi®) Aug 15 (Reuters) - Incyte Corp INCY.O : INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF TAFASITAMAB (MONJUVI®) IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA INCYTE: PHASE 3 INMIND TRIAL MET ITS PRIMARY ENDPOINT INCYTE:EXPECTS TO FILE SUPPLEMENTAL BIOLOGICS

Reuters - 1 month ago

Syndax rises as FDA approves company's treatment for chronic graft-versus-host disease

BUZZ-Syndax rises as FDA approves company's treatment for chronic graft-versus-host disease ** Shares of Syndax Pharmaceuticals SNDX.O rise 4% to $20.37 in afternoon trade ** The U.S. FDA, late on Wednesday, approved Syndax and partner Incyte's INCY.O drug Niktimvo for patients with chronic graft-versus-host disease (GvHD) ** GvHD is a potentially

Reuters - 1 month ago

U.S. Allstate, bluebird bio , Vicinity Motor

U.S. RESEARCH ROUNDUP-Allstate, bluebird bio , Vicinity Motor Aug 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Allstate, bluebird bio and Vicinity Motor, on Thursday. HIGHLIGHTS * Allstate Corp ALL.N : CFRA cuts to hold from buy * Autodesk Inc ADSK.O : Baird raises target price to $295 from $289 * bluebird bio Inc BLUE.O : JP Morgan cuts to neutral from overweight * Provident Financial Services Inc PFS.N : KBW

Reuters - 1 month ago

Incyte, Syndax Get FDA Approval For Niktimvo (axatilimab-csfr)

BRIEF-Incyte, Syndax Get FDA Approval For Niktimvo (axatilimab-csfr) Aug 14 (Reuters) - Incyte Corp INCY.O : INCYTE AND SYNDAX ANNOUNCE U.S. FDA APPROVAL OF NIKTIMVO™ (AXATILIMAB-CSFR) FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) Source text for Eikon: ID:nBw712pWHa Further company coverage: INCY.O

Reuters - 1 month ago

FDA approves Incyte's treatment for chronic graft-versus-host disease

UPDATE 2-FDA approves Incyte's treatment for chronic graft-versus-host disease Rewrites throughout, adds analyst comment in paragraph 9 By Christy Santhosh and Sruthi Narasimha Chari Aug 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Incyte's INCY.O treatment for chronic graft-versus-host disease (GvHD), a potentially fatal complication that could occur after a stem cell transplant.

Reuters - 2 months ago

U.S. Booking Holdings, Doordash, Vertex Pharmaceuticals (Aug. 5)

CORRECTED-U.S. RESEARCH ROUNDUP-Booking Holdings, Doordash, Vertex Pharmaceuticals (Aug. 5) Corrects U.S. research roundup dated Aug. 5 to remove dated research actions from headline and tables, the errors appeared in previous versions also Aug 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Booking Holdings, Doordash and Vertex Pharmaceuticals, on Monday.

Reuters - 2 months ago

Incyte Corp reports results for the quarter ended in June - Earnings Summary

Incyte Corp reports results for the quarter ended in June - Earnings Summary Incyte Corp INCY.OQ reported a quarterly adjusted loss of $1.82 per share for the quarter ended in June, lower than the same quarter last year, when the company reported EPS of 99 cents. The mean expectation of twenty two analysts for the quarter was for a loss of $1.55 per share.

Reuters - 2 months ago

Incyte raises lower end of 2024 sales forecast for blood disorder drug Jakafi

Incyte raises lower end of 2024 sales forecast for blood disorder drug Jakafi July 30 (Reuters) - Incyte Corp INCY.O on Tuesday raised the lower end of the annual sales forecast range for its blood disorder drug Jakafi, on the back of strong demand for the treatment, and also reported better-than-expected quarterly revenue of a newer drug. Shares of the company rose 3.4% before the bell.

Reuters - 2 months ago

Incyte Q2 Adjusted 1.82

BRIEF-Incyte Q2 Adjusted EPS USD -1.82 Jul 30 (Reuters) - Incyte Q2 EPS USD -2.04. Q2 adjusted operating income USD -378.801 million Q2 operating income USD -478.13 million Q2 revenue USD 1,043.759 million

Reuters - 2 months ago

Microsoft and job openings to hit pre-Fed vigil

MORNING BID AMERICAS-Microsoft and job openings to hit pre-Fed vigil A look at the day ahead in U.S. and global markets from Mike Dolan To the extent that worries about pricey tech stocks and rising AI capex spending were partly behind last week's market shakeout, Microsoft's quarterly update should prove a key moment later on Tuesday, just as the Federal Reserve's latest policy meeting gets under way.

Reuters - 2 months ago

Incyte Corp <INCY.OQ> expected to post earnings of $1.11 a share - Earnings Preview

Incyte Corp expected to post earnings of $1.11 a share - Earnings Preview Incyte Corp INCY.OQ INCY.O is expected to show a rise in quarterly revenue when it reports results on July 30 for the period ending June 30 2024 The Wilmington Delaware-based company is expected to report a 6.4% increase in revenue to $1.015 billion from $954.61 million a year ago, according to the mean estimate from 18 analysts, based on LSEG data.

Reuters - 2 months ago

U.S. Alexander & Baldwin, Instructure Holdings, RPM International

U.S. RESEARCH ROUNDUP-Alexander & Baldwin, Instructure Holdings, RPM International July 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alexander & Baldwin, Instructure Holdings and RPM International, on Friday. HIGHLIGHTS * Alexander & Baldwin Inc (Hawaii) ALEX.N : Piper Sandler raises to overweight from neutral * First Financial Northwest Inc FFNW.O : Piper Sandler cuts to neutral from overweight * Instructure H

Reuters - 2 months ago

U.S. BlackRock, Goldman Sachs, Netflix

U.S. RESEARCH ROUNDUP-BlackRock, Goldman Sachs, Netflix July 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BlackRock, Goldman Sachs and Netflix, on Tuesday. HIGHLIGHTS * Ameriprise Financial Inc AMP.N : RBC raises target price to $487 from $480 * BlackRock BLK.N : JP Morgan raises target price to $774 from $756 * Goldman Sachs GS.N : HSBC raises target price to $527 from $493 * Moody's Corp MCO.N : JP Morgan rai

Reuters - 2 months ago

U.S. STOCKS Helios Technologies, Indivior, Principal Financial

BUZZ-U.S. STOCKS ON THE MOVE-Helios Technologies, Indivior, Principal Financial Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq hovered at record highs on Tuesday, propelled by gains in Nvidia and other megacaps, as U.S.

Reuters - 3 months ago

U.S. STOCKS Tesla, Archer Aviation, Novo Nordisk

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Archer Aviation, Novo Nordisk Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 edged up on Tuesday, boosted by gains in Tesla and megacap stocks, while the Dow was flat with investors assessing Federal Reserve Chairman Jerome Powell's comments on the need for more evidence before cutting rates.

Reuters - 3 months ago

U.S. STOCKS Tesla, Pure Storage, Rivian

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Pure Storage, Rivian Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street indexes traded lower on Tuesday after Federal Reserve Chairman Jerome Powell said more evidence was needed before cutting interest rates, while gains in Tesla shares kept losses in check.

Reuters - 3 months ago

U.S. STOCKS PayPal, Paramount Global, Novo Nordisk

BUZZ-U.S. STOCKS ON THE MOVE-PayPal, Paramount Global, Novo Nordisk Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was on track for a lower open on Tuesday as megacap stocks retreated after a strong session, with additional caution creeping in ahead of jobs opening data and comments from Federal Reserve Chairman Jerome Powell later in the day.

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Incyte

News

Conditions

Popular Assets

XM Live Chat